Strengthening Regulatory Framework for Compounded Medications
October 28th 2024Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding explain how the regulatory framework for compounded medications can be further strengthened to ensure quality and safety, while still maintaining flexibility to address patient needs.
Advantages & Disadvantages of Using Compounded Medications
October 24th 2024Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss how compounded medications differ from commercially available drugs in terms of their manufacturing process, quality standards, and more.
Semaglutide Supply Chain & Access Challenges
October 23rd 2024Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss specific challenges that have arisen in the supply chain for semaglutide and how to ensure that patients continue to have access to essential medications, particularly during shortages.
[Sponsored Content] Patient Engagement Throughout the Entire Product Lifecycle
October 21st 2024In the pharmaceutical industry, patient engagement should be centered in health education, communication, and strategy during drug discovery and throughout the product lifecycle. Cheryl Lubbert, CEO of Reverba, discusses the importance of a patient-first mindset in the industry.
Will Pharma Increase Use of Personalized Audio Use in Marketing?
October 21st 2024In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how personalized audio will be utilized within the pharma marketing industry in 2025.
Measuring the ROI of Marketing Efforts
October 18th 2024In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how CMOs effectively measure the return on investment (ROI) of their marketing efforts in the pharmaceutical industry, particularly in light of the long-term nature of drug development and approval processes.
Navigating Social Media Regulatory and Ethical Standards
October 17th 2024In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member explains how pharmaceutical companies can effectively navigate the evolving regulatory landscape and ensure that their marketing activities comply with ethical standards and industry best practices.
Using AI and Advanced Analytics Tools to Optimize Marketing Strategies
October 16th 2024In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how CMOs can leverage artificial intelligence and other advanced analytics tools to extract meaningful insights and optimize marketing strategies.
Balancing Personalized Marketing and Maintaining Data Privacy
October 15th 2024In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how pharmaceutical companies can effectively balance personalized marketing efforts with maintaining data privacy and ensuring patient trust.
Potential Regulatory & Policy Implications
October 1st 2024In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, explains how can companies position themselves to attract VC/federal funding, and identifies potential regulatory and policy implications of these trends.
Areas That Will Benefit Most From Increased VC/Fed Funding
September 30th 2024In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, discusses what specific areas of research and development are likely to benefit the most from this influx of of venture capital and federal funding.
Disposing of Non-Core Assets with Minimal Disruption
September 27th 2024In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, discusses strategies companies employ to effectively identify and dispose of non-core assets while minimizing disruption to their operations.
Attracting Top Talent to Mega Campuses
September 26th 2024In this part of his Pharmaceutical Executive video interview,Jonathan Scheinberg, of the Northeast Science and Technology Center, talks about strategies companies can adopt to attract and retain top talent in these competitive mega campus locations.
Selecting & Developing a Mega Campus
September 25th 2024In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, identifies key factors that pharmaceutical and biotech companies should consider when selecting and developing mega campuses.
Telehealth & Its Role in Providing Access to Weight Loss Drugs
September 16th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, share their predictions for the future of telehealth and its role in providing access to essential medications like weight loss drugs
Increasing Access to Legitimate Weight Loss Medications
September 13th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss how UpScriptHealth is working to increase access to legitimate weight loss medications, especially for those in underserved communities.
Commenting on Eli Lilly's Recent Announcement of Offering Zepbound DTC
September 10th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, comment on how Eli Lilly's recent announcement to sell Zepbound DTC will impact the counterfeit weight loss drug issue.
Counterfeit Weight Loss Drugs & Potential Health Risks
September 9th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, and the potential health risks associated with them.